Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
541-560 of 604 trials

Kidney Transplant: SGLT2 Inhibitor Study

We are investigating whether a new oral medication can improve kidney function in non-diabetic kidney transplant recipients. The study also looks at its safety and effects on overall health compared to a placebo.

Kidney Transplant1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesInternal MedicineNephrology

Durvalumab for Non-Surgical Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of the immunotherapy durvalumab followed by radiation in patients with early stage or locally advanced non-small cell lung cancer. This trial aims to find out if this treatment approach can help those who cannot have surgery.

Non-Small Cell Lung Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Triple-Negative Breast Cancer: Dato-DXd Treatment

We are studying a new drug for patients with triple-negative breast cancer and brain metastases to see if it can help shrink tumors and improve survival. The trial also examines safety and quality of life for participants.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Palmoplantar Pustulosis: Delgocitinib Cream Study

We are investigating whether delgocitinib cream can effectively treat adults with mild to severe palmoplantar pustulosis compared to a dummy cream. The study will also assess the safety and impact on quality of life.

Palmoplantar Pustulosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesDermatology

Nintedanib for Nosebleeds in Hereditary Hemorrhagic Telangiectasia

We are studying whether nintedanib can help reduce the duration of nosebleeds in patients with hereditary hemorrhagic telangiectasia. The trial also examines its effects on quality of life and potential side effects.

Hereditary Hemorrhagic Telangiectasia1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHematologyInternal Medicine

Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis

We are studying a new treatment using neural stem cells for people with ALS. The trial aims to assess safety and whether it may help slow disease progression.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Ulcerative Colitis and Crohn’s Disease: Long-term Study of Zasocitinib

We are investigating the long-term safety and effectiveness of oral zasocitinib in adults with moderately to severely active ulcerative colitis and Crohn’s disease. This study is for those who have responded to treatment in previous trials.

Ulcerative ColitisCrohn's Disease>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Knee Osteoarthritis: Study of 4P004 Treatment

We are investigating whether the treatment 4P004 can reduce pain and improve function in people with knee synovitis and osteoarthritis. Participants will receive either the treatment or a placebo to assess its effectiveness and safety.

Knee Synovitis and Osteoarthritis≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Cardiac Arrest: Landiolol Treatment Study

We are testing whether adding landiolol can help patients who have had a cardiac arrest regain a stable heartbeat faster. This study will also look at overall survival and safety outcomes.

Cardiac Arrest and Ventricular Fibrillation6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation Prevention: Landiolol Hydrochloride

We are studying whether Landiolol hydrochloride can help prevent atrial fibrillation in patients undergoing heart surgery. This trial looks at how often this condition occurs in the days following the surgery.

Normal Heart RhythmNormal Ejection FractionBeta-blocker Use≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Worsening Heart Failure: COR-1167 Treatment Study

We are testing a new medication for people with worsening heart failure to see how it affects symptoms and heart health. The study will also check the safety and tolerability of this treatment.

Worsening Heart Failure≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Riluzole for Spinocerebellar Ataxia Type 7

We are studying whether Riluzole can help patients with Spinocerebellar Ataxia type 7 maintain their stability in symptoms and visual function. This trial will also assess the safety and tolerability of the medication.

Spinocerebellar Ataxia Type 7 (SCA7)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology

Neurotrophic Keratopathy: RGN-259 Eye Drops

We are studying a new eye drop solution for people with Neurotrophic Keratopathy. The trial will compare its effects to a placebo to see if it improves eye health.

Neurotrophic Keratitis≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Felzartamab for Kidney Transplant Recipients with Late Antibody-Mediated Rejection

We are studying whether felzartamab can improve outcomes for kidney transplant recipients facing late antibody-mediated rejection. This trial compares the new treatment to a placebo to assess its effectiveness and safety.

Kidney Transplant Rejection1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNephrology

Esketamine for Schizophrenia Symptoms

We are studying whether esketamine can reduce depressive and negative symptoms in people with schizophrenia. The trial also looks at whether it causes any worsening of psychotic symptoms.

Negative and Depressive Symptoms in Schizophrenia and Schizoaffective Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Blood Cancers: IDP-121 Treatment Study

We are testing a new medication, IDP-121, for patients with relapsed or refractory blood cancers like multiple myeloma and B-cell lymphoma. The goal is to find the best dose and see how well it helps improve patient outcomes.

Chronic Lymphocytic Leukemia (CLL)B-cell LymphomasMultiple Myeloma (MM)6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Glioblastoma Multiforme: Itraconazole with Radiotherapy and Temozolomide

We are studying whether adding Itraconazole to standard radiotherapy and temozolomide is safe for patients with newly diagnosed glioblastoma. Our goal is to find the best dose and understand its effects on survival and quality of life.

Glioblastoma≤3 monthsSafety phase (I)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Cervical Dystonia: IPN10200 Treatment Study

We are studying the effects of IPN10200 on reducing symptoms of cervical dystonia in adults. This trial will help us understand if it can improve pain and disability compared to a placebo.

Cervical Dystonia6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

UTI Vaccine Study for Adults Aged 18-64

We are testing a new vaccine to see if it can safely prevent urinary tract infections caused by E. coli in adults, especially women. The study will compare its effectiveness to a placebo.

Urinary Tract Infections1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology